1. Advanced Soft Tissue Sarcoma: Current and Future

3. Program Introduction

4. Sarcoma Histologic Subtypes

5. Molecular Subtypes of Sarcoma

6. Histology Subtypes

7. Drugs and Subtypes

8. Advanced STS: Mono vs Poly Chemotherapy

9. Doxorubicin vs Intensified Doxorubicin Plus Ifosfamide for Advanced STS: Phase 3

10. Gemcitabine Plus Docetaxel vs Doxorubicin as First-Line Therapy in Metastatic STS: Phase 3 GeDDis Trial

11. Systemic Therapies for Advanced Pretreated STS

12. Trabectedin vs Dacarbazine in Advanced LMS and LPS: SAR-3007

13. Eribulin vs Dacarbazine: Phase 3 Trial

14. Pazopanib for Metastatic STS: Phase 3 PALETTE Trial

15. Pazopanib in Advanced and/or Metastatic LPS: Phase 2 GEIS-30/GISG-07

16. PDGFR

17. PFS for Olaratumab + Doxorubicin vs Doxorubicin Alone (ITT Population)

18. OS for Olaratumab + Doxorubicin vs Doxorubicin Alone (ITT Population)

19. Olaratumab Safety

20. Molecular Subtypes of Sarcoma

21. M-CSFR Inhibitors in PVNS With t(1,2)

22. Effect of RG7112 on the p53 Pathway in MDM-2 Amplified Advanced WD/DD LPS

23. Palbociclib in CDK4 Amplified Advanced WD/DD LPS

24. Conclusions